Argireline is the trade name for acetyl hexapeptide-3 (also renamed acetyl hexapeptide-8 under current INCI naming), a synthetic peptide developed by the cosmetic-ingredient company Lipotec and used in topical skincare products aimed at softening the look of expression lines. It is applied to the skin, not injected, and works through a mechanism that loosely resembles botulinum toxin’s effect on the small muscles responsible for facial expression lines, though the evidence for a meaningful cosmetic effect from topical use is modest and mixed.
Research snapshot
| Peptide category | Synthetic acetylated cosmetic hexapeptide, designed to mimic a fragment of SNAP-25 |
| Primary research interest | Topical softening of the look of expression lines (botulinum-toxin-like mechanism, applied to skin rather than injected) |
| Highest available evidence | Cosmetic-industry and CIR-panel safety review; evidence for a meaningful cosmetic effect from topical use is described as modest and mixed |
| Human research available | Some cosmetic-efficacy studies exist; overall evidence is modest and mixed rather than robust clinical-trial-grade evidence |
| Development status | Established cosmetic ingredient, developed and patented by Lipotec |
| Regulatory status | Regulated as a cosmetic ingredient, not a drug, in the US, EU, and most markets; reviewed and found safe at surveyed concentrations by the US Cosmetic Ingredient Review (CIR) panel; not FDA-approved as a drug and makes no approved therapeutic claims |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Argireline (trade name); acetyl hexapeptide-3 |
| Alternative names | Acetyl hexapeptide-8 (current INCI naming) |
| Peptide sequence | Acetyl-Glu-Glu-Met-Gln-Arg-Arg-amide |
| Amino-acid length | 6 (hexapeptide) |
| Molecular formula | Not independently re-verified in this pass |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| Chemical modifications | N-terminal acetylation; C-terminal amidation |
| Peptide class | Cosmetic neuropeptide, designed to mimic a fragment of SNAP-25 |
| Primary biological target | Proposed to interfere with SNARE-complex-mediated neurotransmitter release at the neuromuscular junction, loosely resembling botulinum toxin’s mechanism |
| Developer or originator | Lipotec (Spain) |
| Development status | Established, commercially available cosmetic ingredient |
What it is
Argireline is a synthetic hexapeptide (a chain of six amino acids) with the sequence acetyl-Glu-Glu-Met-Gln-Arg-Arg-amide, designed to mimic a fragment of a natural protein called SNAP-25. SNAP-25 is one of several proteins that nerve cells use to release neurotransmitters at the point where a nerve signal tells a muscle to contract. It was developed and patented by the Spanish cosmetic ingredient company Lipotec (later part of Lubrizol / IFF) and introduced commercially under the Argireline brand in the early 2000s, becoming one of the most widely used “peptide” actives in over-the-counter anti-wrinkle cosmetics.
Under current INCI (International Nomenclature of Cosmetic Ingredients) naming rules, the same peptide is now formally listed as Acetyl Hexapeptide-8, with Acetyl Hexapeptide-3 recognized as the ingredient’s earlier or synonym name; product labels and technical literature use both terms, sometimes for the identical substance. Argireline is not a drug and is not designed or approved to treat any medical condition — it is formulated exclusively as a cosmetic ingredient intended to be applied to the skin surface in creams, serums, and gels.
It became popular because its proposed mechanism offered a topical, needle-free alternative to the idea behind botulinum toxin injections, and because early industry-sponsored studies reported measurable reductions in wrinkle depth with regular use. It remains widely used today, typically as one active among several in “anti-aging” or “expression line” formulations, rather than as a standalone treatment.
How does it work?
Plain-English explanation
Facial expression lines (like crow’s feet or forehead lines) form partly because small facial muscles repeatedly contract. Botulinum toxin injections work by blocking the nerve signal that tells those muscles to contract. Argireline is proposed to interfere with a similar step in that signaling chain, but from outside the cell and applied to the skin surface rather than injected into muscle — the idea being to gently reduce the strength of that nerve-to-muscle signal so the muscle contracts a bit less forcefully, which in theory could soften the look of expression lines over time. Because it never enters the muscle tissue the way an injection does, any effect is expected to be far more modest than botulinum toxin’s.
Technical explanation
The proposed mechanism is that Argireline’s peptide sequence, structurally related to a portion of SNAP-25, may partially inhibit the formation of the SNARE complex — the group of proteins (including SNAP-25, syntaxin, and VAMP) responsible for docking and releasing neurotransmitter-containing vesicles at the neuromuscular junction. By competing with the natural SNAP-25 fragment, the peptide is theorized to modestly reduce acetylcholine release, which would in turn reduce the strength of the muscle contraction signal. Skin-penetration studies commissioned to evaluate the ingredient have reported that only a very small fraction (well under 1%) of topically applied peptide penetrates the outer skin layers within 24 hours, which is an important limitation on how much of this proposed neuromuscular mechanism could realistically occur from a cream or serum applied to intact skin, as opposed to an injected product.
Potential benefits and research applications
Reduced appearance of expression lines
What is being investigated: whether regular topical application softens the visible depth of expression lines such as crow’s feet and forehead lines. How the effect might occur: through the proposed partial inhibition of neurotransmitter release at the neuromuscular junction described above. Evidence: several small, mostly industry-funded or industry-affiliated human cosmetic trials have reported measurable reductions in wrinkle depth (in the roughly 10-30% range over several weeks) using instrumental skin-surface measurement, and a 2025 review noted improvements in wrinkle appearance with inconsistent statistical significance, with more consistent results reported when the peptide was combined with other active ingredients rather than used alone. Strength: preliminary human observational/small-clinical-trial evidence, not confirmed by large independent trials. Limitation: many published studies are small, short in duration, sponsored or co-authored by the ingredient supplier, and rely on instrumental surface measurement rather than blinded clinical grading; independent large-scale replication is limited.
Extending the effect of botulinum toxin injections
What is being investigated: whether applying acetyl hexapeptide cream alongside botulinum toxin injections extends the visible duration of the toxin’s effect. How the effect might occur: a proposed additive reduction in neuromuscular signaling on top of the toxin’s effect. Evidence: at least one small double-blind clinical study (in blepharospasm, an eyelid-spasm condition, not cosmetic wrinkle treatment) reported an extended duration of symptom relief when the peptide cream was used alongside botulinum toxin compared with toxin plus placebo cream. Strength: preliminary, based on a single small clinical study in a medical condition rather than cosmetic wrinkle reduction. Limitation: has not been established for cosmetic use, and this is a single study that has not been widely replicated.
General “relaxed muscle” cosmetic marketing claims
What is being investigated: broader claims describing Argireline as a topical “muscle relaxant” for the face. How the effect might occur: same proposed SNARE-complex mechanism described above. Evidence: this framing is largely a marketing simplification of the modest, preliminary human data described above. Strength: has not been established as a meaningful muscle-relaxing effect comparable to botulinum toxin; skin-penetration data suggests the effect, if present, is limited by how little peptide actually reaches deeper tissue. Limitation: comparisons to botulinum toxin in promotional material substantially overstate the strength of the underlying evidence.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. Because Argireline is a topical cosmetic ingredient rather than an injected or oral compound, the figures that matter here are formulation concentrations (the percentage of the ingredient in a finished cream or serum) rather than a dose taken into the body.
Amounts studied in human research
Published cosmetic-efficacy studies on acetyl hexapeptide-8/3 have used the ingredient at concentrations reported in the low single-digit percentage range (published examples describe roughly 10% of a peptide-containing solution or complex incorporated into a cream base, applied topically to periorbital or facial skin twice daily for periods of roughly 15 to 60 days). It is important to note that this reported “10%” generally refers to the concentration of a diluted peptide solution or delivery complex added to the formula, not 10% pure peptide by weight in the finished product — cosmetic industry usage-concentration surveys (see below) report the actual pure-peptide content of marketed leave-on products as far lower, in the thousandths-of-a-percent range.
Amounts studied in animal research
Not consistently reported. Available published work on this ingredient is concentrated in human skin-penetration and cosmetic-efficacy studies and in-vitro (cell-culture) mechanism work rather than whole-animal dosing studies.
Practitioner and community-reported protocols
Formulators and skincare-industry sources (community/vendor-reported tier) commonly cite finished-product concentrations in the range of roughly 5-10% of a peptide-complex ingredient (again, a diluted delivery-solution concentration, not pure peptide), typically formulated at pH-appropriate levels and applied once or twice daily as part of a broader serum or cream. Independent U.S. Cosmetic Ingredient Review (CIR) industry survey data for the underlying pure peptide reports maximum reported use concentrations of approximately 0.005% in leave-on facial and eye-area products, and roughly 0.000005% in rinse-off products, based on manufacturer-submitted formulation data. These CIR figures represent the most independently sourced, verifiable formulation-concentration data available for this ingredient.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Topical anti-wrinkle formulation (leave-on facial/eye product) | Topical (skin) | Up to ~0.005% pure peptide (leave-on max) | Once or twice daily, as formulated | Ongoing with regular product use; published studies commonly ran 15-60 days |
| Topical anti-wrinkle formulation (rinse-off product) | Topical (skin), rinsed off | Up to ~0.000005% pure peptide (rinse-off max) | Not consistently reported | Not consistently reported |
| Published cosmetic-efficacy research studies | Topical (skin) | ~10% peptide-complex solution (not pure peptide) | Typically twice daily | Commonly 15 to 60 days in cited studies |
Because Argireline is a topical cosmetic ingredient rather than an injected or oral compound, the figure that actually circulates and matters is a formulation concentration, not a body dose. Independent, verifiable data comes from the U.S. Cosmetic Ingredient Review (CIR) industry-use survey, which reports maximum reported concentrations of roughly 0.005% pure peptide in leave-on facial and eye products and roughly 0.000005% in rinse-off products, based on manufacturer-submitted formulation data.
Separately, published cosmetic-efficacy studies commonly describe testing a peptide-containing solution or "complex" at around 10% of the finished formula. This figure is frequently repeated in secondary and vendor sources as though it represents 10% pure peptide, which appears inconsistent with the much lower pure-peptide percentages reported in the CIR industry survey; this discrepancy has not been clearly resolved in the sources reviewed and readers should not assume the two figures describe the same thing.
No dosing information applies in the injected or oral sense, since Argireline is formulated and used exclusively as a topical cosmetic ingredient.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Published human studies and the U.S. Cosmetic Ingredient Review safety assessment of acetyl hexapeptide-8/8 amide have generally reported the ingredient as non-irritating and well tolerated at the concentrations studied, without significant reported skin irritation or sensitization in the trials reviewed. Skin-penetration studies have found that only a small fraction of applied peptide penetrates beyond the outermost skin layer, which is reassuring from a systemic-absorption standpoint but also underscores why any neuromuscular effect from topical use should be expected to be limited compared with an injected product. As with any cosmetic peptide ingredient, formulation quality (concentration accuracy, stability, and preservation) varies across manufacturers, and claims comparing this ingredient directly to botulinum toxin injections substantially overstate what has been established in the underlying research. No meaningful long-term safety concerns specific to this ingredient at cosmetic-use concentrations have been identified in the sources reviewed.
Regulatory and developmental status
Argireline (acetyl hexapeptide-3 / acetyl hexapeptide-8) is regulated as a cosmetic ingredient, not a drug, in the United States, European Union, and most other markets, meaning it is not subject to the clinical-trial approval pathway required for pharmaceuticals. It has undergone a formal ingredient safety review by the U.S. Cosmetic Ingredient Review (CIR) expert panel, which found it safe for use in cosmetics at the concentrations reported in industry-use surveys. It is not FDA-approved as a drug and makes no approved therapeutic claims; any drug-like claims made about it in marketing exceed its regulatory status as a cosmetic ingredient. Status verified as of the date below.
Frequently asked questions
What is Argireline?
Argireline is the brand name for acetyl hexapeptide-3/8, a synthetic six-amino-acid peptide used as a topical cosmetic ingredient marketed for softening the appearance of expression lines.
How does Argireline work?
It is proposed to modestly interfere with the SNARE-complex signaling process that triggers muscle contraction at the neuromuscular junction, similar in concept to (but far weaker than) botulinum toxin, though skin-penetration studies suggest limited amounts actually reach that target from topical use.
What concentration has been studied in research?
Published cosmetic-efficacy studies have used peptide-complex solutions incorporated at roughly the low single-digit-to-10% range within a cream base; this refers to a diluted delivery solution, not pure peptide, and should not be confused with the much lower pure-peptide percentages reported in finished commercial products.
What concentration circulates in commercial skincare products?
Independent industry survey data (U.S. CIR) reports maximum pure-peptide use concentrations of approximately 0.005% in leave-on products.
Is Argireline the same as Botox?
No. It is a topical cosmetic peptide with a proposed mechanism loosely related to botulinum toxin’s target, but it is not injected, has far more limited tissue penetration, and has not been shown to produce an effect comparable to botulinum toxin injections.
Has Argireline been studied in humans?
Yes, in several small, mostly industry-affiliated cosmetic-efficacy trials measuring wrinkle depth with instrumental skin measurement, plus at least one small clinical study in blepharospasm; independent, large-scale clinical trials are limited.
What side effects have been reported?
Published studies and the CIR safety review report it as generally non-irritating and well tolerated at studied cosmetic concentrations, with no major safety concerns identified.
Is Argireline FDA-approved?
It is not a drug and is not subject to FDA drug approval; it is regulated as a cosmetic ingredient and has passed an independent cosmetic-ingredient safety review (CIR).
How strong is the evidence overall?
Preliminary. Human cosmetic-efficacy data exists but is generally small-scale, short-term, and often industry-affiliated; effects appear modest, and results are more consistent in multi-ingredient formulations than for the peptide used alone.
What remains unknown?
The real-world magnitude of any independent, non-sponsor-funded clinical effect, how much of the studied “10%” figure reflects pure peptide versus diluted complex, and long-term outcomes with sustained daily use have not been clearly established.
Bottom line
Argireline is a well-established, industry-reviewed cosmetic peptide ingredient with a plausible but modest proposed mechanism and a body of mostly small, industry-affiliated human studies suggesting some reduction in wrinkle appearance, more consistently when combined with other actives. It is not equivalent to botulinum toxin, and claims implying otherwise overstate the evidence. The genuinely verifiable “dosage” figure for this ingredient is a formulation concentration: independent industry survey data puts real-world leave-on product concentrations at roughly 0.005% or less, which is far lower than the “10%” figure sometimes quoted from delivery-solution research studies. It is a cosmetic ingredient, not a drug, with no FDA approval and no established medical indication.